Pasithea

Contributing Author

Recent Articles by Pasithea

Aug-29	Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference KTTA GlobeNewswire
Aug-28	Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference KTTA GlobeNewswire
Jul-31	Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Jun-11	Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board KTTA GlobeNewswire
Jun-02	Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 KTTA GlobeNewswire
May-20	Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases KTTA GlobeNewswire
May-14	Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site KTTA GlobeNewswire
May-07	Pasithea Therapeutics Announces Closing of $5 Million Public Offering KTTA GlobeNewswire
May-06	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering KTTA GlobeNewswire
May-06	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 KTTA GlobeNewswire